No Way to Verify Legitimacy or True Cost of High-Risk Payment Processors

Summary

Merchants in restricted verticals (peptides, supplements, CBD, vape and similar) are quoted opaque, exorbitant terms by specialized 'high-risk' processors—e.g. 8.9% + $0.40 per transaction with a 10% rolling reserve—while being asked to buy unrelated, cloaked domains that hide their real business from the acquiring bank. Because the pricing, reserve terms, and cloaking requirements are non-transparent and impossible to benchmark, merchants cannot tell whether the processor is simply passing through real acquiring-bank costs or is cloaking the business and pocketing a huge margin at the merchant's expense. No independent comparison source or truth-in-fee disclosure exists for high-risk processing, so operators are forced to gamble their revenue on unverifiable claims, made worse by mainstream processors like Stripe having already terminated them. This is unsolved, extremely painful, and highly relevant to 'The Decline File': merchants know the 6%–12%+ rates and reserve holds are brutal but have no reliable way to validate which providers genuinely accept their category or what the real, all-in switching cost will be.